Navigation Links
Oppenheimer Announces the Addition of Several Recent Senior Hires in Investment Banking
Date:3/17/2009

NEW YORK, March 17 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., is pleased to announce the addition of several recent senior hires in the Investment Banking Department.

Brian A. McCarthy has joined the firm as the Head of our Healthcare Investment Banking Group. Brian has more than 20 years of investment banking experience and most recently served as Co-head of Global Healthcare at JPMorgan. Prior to JPM, Brian spent seven years at Lehman Brothers where he was also Co-head of Healthcare. Brian has extensive experience in multiple healthcare subsectors and a proven track record of serving as a trusted advisor to his clients. Brian will report to Marshall A. Heinberg, Senior Managing Director and Head of Investment Banking at Oppenheimer.

Joining Brian as a Managing Director in Healthcare is Jaime Burnes. Jaime most recently was a member of the Healthcare Group at Credit Suisse. Jaime had been with Credit Suisse since 2006, generating and executing financing and M&A transactions in the biotechnology and specialty pharmaceutical sectors. Prior to working at Credit Suisse, Jaime worked for Lehman Brothers. At Oppenheimer, Jaime will continue his focus on the life sciences space.

Also joining the firm as a Director in Healthcare is Eric Rabinowitz. Eric joins Oppenheimer from JPMorgan (and before that Bear Stearns) where he was a Vice President in the Healthcare Group. Eric had been with Bear Stearns since 2003 advising clients and executing transactions across multiple healthcare subsectors. At Oppenheimer, Eric will focus on the healthcare services space.

David Sommer has joined our Financial Sponsors Group as a Managing Director. David has approximately fifteen years of investment banking experience and most recently was a Managing Director in the Financial Sponsor Group at JPMorgan. Prior to JPM, David spent nine years at CIBC World Markets Corp. where he was a Managing Director in the Financial Sponsor/Leveraged Finance Group. David has also worked in the Leveraged Finance Group at JPMorgan and at the General Electric Company in Corporate Business Development. David has a proven track record of generating equity, M&A, and leveraged finance business with financial sponsors and their portfolio companies.

Jeffrey Berson has joined our Technology and Telecom Group as a Managing Director. Jeff joins us from Barclays Capital where he was a Managing Director in the Telecom Group. Jeff had been with Barclays since 2007 focusing on the Wireline, Wireless and Emerging Telecom sectors. Prior to working at Barclays, Jeff worked for CIBC World Markets in the Technology & Telecom Group. At Oppenheimer, Jeff will continue his coverage of growth companies in both the wireline and wireless sectors.

"We are delighted to be able to recruit such an outstanding roster of high quality professionals to our firm," noted Marshall Heinberg. "Each of these individuals are proven bankers who are well positioned to serve their clients at Oppenheimer. We have witnessed a tremendous opportunity to recruit seasoned bankers who are well versed in delivering a full suite of banking products to our middle market clients."

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
2. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
3. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
6. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Beckman Coulter to Present at the Oppenheimer Annual Healthcare Conference
8. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
9. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
10. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... 23, 2016 , ... Velocity Products, a division of Morris ... optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, ... several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):